Zevra Therapeutics, Inc. (ZVRA) compared with its closest peers (SUPN, COLL, GYRE, NRIX, RGNX): P/E 12.2 vs industry 15.1. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Supernus Pharmaceuticals and Collegium Pharmaceutical: named a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | $2.42B | — |
| Collegium Pharmaceutical, Inc. (COLL) | $740.97M | 15.5 |
| Gyre Therapeutics, Inc. (GYRE) | $751.02M | 73.5 |
| Nurix Therapeutics, Inc. (NRIX) | $2.60B | — |
| REGENXBIO Inc. (RGNX) | $563.09M | — |
| Eton Pharmaceuticals, Inc. (ETON) | $1.63B | 128.6 |
| Agios Pharmaceuticals, Inc. (AGIO) | $2.00B | — |
| Stoke Therapeutics, Inc. (STOK) | $1.81B | — |
| MacroGenics, Inc. (MGNX) | $254.80M | — |
| Rhythm Pharmaceuticals, Inc. (RYTM) | $7.21B | — |
| Stock P/E | 12.2 |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| vs Sector | -37.3% |
| vs Industry | -19.5% |
ZVRA overview · ZVRA earnings · ZVRA financials · ZVRA KPIs · ZVRA documents · ZVRA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.